
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is a dominant player in the pharmaceutical industry with a strong portfolio of products and a diverse pipeline focused on addressing major healthcare needs. The company's strong sales forecast and forecasted EPS growth suggest a strong future performance. Additionally, the company's commitment to sustainability and focus on diversity and inclusion in clinical trials show long-term potential for consistent growth and market leadership. Potential downside risks include pricing pressure and competition in the GLP-1 market, as well as potential negative pipeline trial results. As a result, an Outperform rating is appropriate with a 12-month price target of $1,500, based on a 30x multiple on forward fully diluted operating EPS forecast.
Bears say
Eli Lilly is a well-established pharmaceutical company with a diverse portfolio including products in neuroscience, cardiometabolic, cancer, and immunology. However, due to concerns surrounding slowing growth and potential pricing pressures in key products like Mounjaro and Trulicity, as well as uncertainties around the success of pipeline products such as Foundayo and retatrutide, our negative outlook for the stock is based on the potential for underperformance in the market. Furthermore, while the company has several promising potential catalysts in the horizon which could drive growth, the perceived high valuation and potential market-cap risks may overshadow these potential positive developments.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares